Acceleron Pharma And Celgene Corporation (CELG) Announce Interim Clinical Data For Sotatercept In Patients With End Stage Renal Disease On Hemodialysis At The 2014 National Kidney Foundation Spring Clinical Meeting
3/18/2014 9:10:02 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, will present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV.
Help employers find you! Check out all the jobs and post your resume.
comments powered by